Product Introduction:
Myaza 100mg contains Azacitidine, a DNA methylation inhibitor used in the treatment of blood cancers. It works by interfering with abnormal cell division and helping restore the bone marrow's ability to produce healthy blood cells. This injectable form is administered under the skin or into a vein by medical professionals, typically in treatment cycles.
Uses:
Myaza 100mg is primarily used for:
-
Myelodysplastic Syndromes (MDS) – all French-American-British (FAB) subtypes
-
Chronic Myelomonocytic Leukemia (CMML)
-
Acute Myeloid Leukemia (AML) in elderly or unfit patients
-
Treatment of bone marrow failure syndromes
-
Delaying disease progression from MDS to AML
-
Improving low blood counts (anemia, neutropenia, thrombocytopenia)
Storage Instructions:
-
Store at 2°C to 8°C (refrigerated)
-
Protect from light and moisture
-
Reconstituted solution should be used promptly or within the specified stability window
-
Do not freeze
-
Keep away from children
How It Works (Mechanism of Action):
Azacitidine is a cytidine nucleoside analog that becomes incorporated into DNA and RNA, leading to inhibition of DNA methyltransferase enzymes. This hypomethylation reactivates suppressed genes that regulate cell growth and apoptosis, thereby reducing cancer cell proliferation and enabling healthy hematopoietic cell production.
Side Effects:
Common side effects include:
-
Injection site irritation or pain
-
Nausea, vomiting, constipation
-
Fatigue and weakness
-
Anemia, low platelet or white blood cell counts
-
Fever or mild infections
Serious side effects may include:
-
Bone marrow suppression leading to severe infections or bleeding
-
Sepsis
-
Liver or kidney dysfunction
-
Severe allergic reactions (anaphylaxis, rash, breathing issues)
Dosage (Typical Recommended Dose):
-
Standard dose: 75 mg/m² daily for 7 consecutive days in a 28-day cycle
-
Treatment is often continued for at least 6 cycles to assess clinical benefit
-
Dosage may be modified based on blood test results and side effects
Method of Administration:
-
Administered via subcutaneous injection or intravenous infusion
-
Reconstitution required before use with sterile water for injection
-
To be given by trained medical professionals only
-
Anti-nausea medications may be used prior to dosing
Precautions:
-
Monitor blood cell counts regularly
-
Use with caution in patients with renal or hepatic impairment
-
Not recommended during pregnancy or lactation – may harm the unborn baby
-
Use effective contraception during treatment
-
Patients should avoid people with active infections due to immunosuppression
Drug Interactions:
-
Use with other myelosuppressive agents can increase risk of side effects
-
Caution with nephrotoxic or hepatotoxic drugs
-
Limited CYP450 interactions, but monitor with other chemotherapy agents
Allergies:
-
Contraindicated in patients with known hypersensitivity to Azacitidine or mannitol
-
Watch for signs of allergic reaction: rash, swelling, dizziness, difficulty breathing
Overdose Information:
-
Overdose may cause severe bone marrow suppression, infections, or bleeding
-
Immediate medical attention and supportive treatment are required
-
Hospitalization may be necessary
Missed Dose Instructions:
-
Do not skip or delay doses during a treatment cycle
-
If a dose is missed, consult your doctor immediately for rescheduling
-
Do not double the dose to make up for a missed one
Additional Notes:
-
Periodic bone marrow evaluations may be required to assess response
-
Supportive care such as transfusions or antibiotics may be needed
-
Continue treatment as prescribed, even if no immediate improvement is visible
-
Discuss all ongoing medications and herbal supplements with your doctor before starting
Product Introduction:
Myaza 100mg contains Azacitidine, a DNA methylation inhibitor used in the treatment of blood cancers. It works by interfering with abnormal cell division and helping restore the bone marrow's ability to produce healthy blood cells. This injectable form is administered under the skin or into a vein by medical professionals, typically in treatment cycles.
Uses:
Myaza 100mg is primarily used for:
-
Myelodysplastic Syndromes (MDS) – all French-American-British (FAB) subtypes
-
Chronic Myelomonocytic Leukemia (CMML)
-
Acute Myeloid Leukemia (AML) in elderly or unfit patients
-
Treatment of bone marrow failure syndromes
-
Delaying disease progression from MDS to AML
-
Improving low blood counts (anemia, neutropenia, thrombocytopenia)
Storage Instructions:
-
Store at 2°C to 8°C (refrigerated)
-
Protect from light and moisture
-
Reconstituted solution should be used promptly or within the specified stability window
-
Do not freeze
-
Keep away from children
How It Works (Mechanism of Action):
Azacitidine is a cytidine nucleoside analog that becomes incorporated into DNA and RNA, leading to inhibition of DNA methyltransferase enzymes. This hypomethylation reactivates suppressed genes that regulate cell growth and apoptosis, thereby reducing cancer cell proliferation and enabling healthy hematopoietic cell production.
Side Effects:
Common side effects include:
-
Injection site irritation or pain
-
Nausea, vomiting, constipation
-
Fatigue and weakness
-
Anemia, low platelet or white blood cell counts
-
Fever or mild infections
Serious side effects may include:
-
Bone marrow suppression leading to severe infections or bleeding
-
Sepsis
-
Liver or kidney dysfunction
-
Severe allergic reactions (anaphylaxis, rash, breathing issues)
Dosage (Typical Recommended Dose):
-
Standard dose: 75 mg/m² daily for 7 consecutive days in a 28-day cycle
-
Treatment is often continued for at least 6 cycles to assess clinical benefit
-
Dosage may be modified based on blood test results and side effects
Method of Administration:
-
Administered via subcutaneous injection or intravenous infusion
-
Reconstitution required before use with sterile water for injection
-
To be given by trained medical professionals only
-
Anti-nausea medications may be used prior to dosing
Precautions:
-
Monitor blood cell counts regularly
-
Use with caution in patients with renal or hepatic impairment
-
Not recommended during pregnancy or lactation – may harm the unborn baby
-
Use effective contraception during treatment
-
Patients should avoid people with active infections due to immunosuppression
Drug Interactions:
-
Use with other myelosuppressive agents can increase risk of side effects
-
Caution with nephrotoxic or hepatotoxic drugs
-
Limited CYP450 interactions, but monitor with other chemotherapy agents
Allergies:
-
Contraindicated in patients with known hypersensitivity to Azacitidine or mannitol
-
Watch for signs of allergic reaction: rash, swelling, dizziness, difficulty breathing
Overdose Information:
-
Overdose may cause severe bone marrow suppression, infections, or bleeding
-
Immediate medical attention and supportive treatment are required
-
Hospitalization may be necessary
Missed Dose Instructions:
-
Do not skip or delay doses during a treatment cycle
-
If a dose is missed, consult your doctor immediately for rescheduling
-
Do not double the dose to make up for a missed one
Additional Notes:
-
Periodic bone marrow evaluations may be required to assess response
-
Supportive care such as transfusions or antibiotics may be needed
-
Continue treatment as prescribed, even if no immediate improvement is visible
-
Discuss all ongoing medications and herbal supplements with your doctor before starting
